Disease Domain | Count |
---|---|
Infectious Diseases | 5 |
Nervous System Diseases | 2 |
Neoplasms | 2 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Growth factors | 2 |
Prophylactic vaccine | 2 |
mRNA vaccine | 2 |
Immunoglobulin | 1 |
ASO | 1 |
Target- |
Mechanism- |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date14 Sep 2022 |
Target- |
Mechanism Immunostimulants |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date16 Nov 2017 |
Target |
Mechanism c-Met modulators |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jul 2024 |
Sponsor / Collaborator Tsinghua University [+1] |
Start Date30 May 2023 |
Sponsor / Collaborator |
Start Date07 May 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Recombinant plasmid-hepatocyte growth factor(Academy of Military Medical Sciences) ( c-Met ) | Lower limb ischemia More | Phase 3 |
Recombinant adenovirus-hepatocyte growth factor(Academy of Military Medical Sciences) | Myocardial Ischemia More | Phase 2 |
CT102 ( IGF-1R ) | Hepatocellular Carcinoma More | Phase 2 |
Ametumumab ( EGFR ) | RAS Wild Type Colorectal Cancer More | Phase 2 |
Adenovirus type 5 vector based ebola virus disease vaccine(CanSino Biologics, Inc.) | Hemorrhagic Fever, Ebola More | Phase 2 |